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ABSTRACT
The generation of myeloid cells from their progenitors is
regulated at the level of transcription by combinatorial
control of key transcription factors influencing cell-fate
choice. To unravel the global dynamics of this process at the
transcript level, we generated transcription profiles for 91
human cell types of myeloid origin by use of CAGE profiling.
The CAGE sequencing of these samples has allowed us to
investigate diverse aspects of transcription control during
myelopoiesis, such as identification of novel transcription
factors, miRNAs, and noncoding RNAs specific to the
myeloid lineage. We further reconstructed a transcription
regulatory network by clustering coexpressed transcripts
and associating them with enriched cis-regulatory motifs.
With the use of the bidirectional expression as a proxy for
enhancers, we predicted over 2000 novel enhancers, in-
cluding an enhancer 38 kb downstream of IRF8 and an
intronic enhancer in the KIT gene locus. Finally, we high-
lighted relevance of these data to dissect transcription
dynamics during progressive maturation of granulocyte
precursors. A multifaceted analysis of the myeloid tran-
scriptome ismadeavailable (www.myeloidome.roslin.ed.ac.
uk). This high-quality dataset provides a powerful resource
to study transcriptional regulationduringmyelopoiesis and to
infer the likely functions of unannotated genes in human
innate immunity. J. Leukoc. Biol. 97: 985–995; 2015.
Introduction
Myeloid cells are a family of innate immune cells derived from
pluripotent stem cells via a common, committed progenitor. They
differentiate to become innate immune effector cells in response
to various lineage-restricted growth factors, including CSF-1,
GM-CSF, IL-3, IL-34, FLT3, and stem cell factor [1]. Each myeloid
cell type has a distinct function and a set of gene products
facilitating that function. Many genome-scale expression datasets
have been generated in mouse and human systems to deﬁne the
genes that distinguish different myeloid cell types [2, 3] and the
underlying transcriptional regulatory networks [4, 5]. For
example, the gene-expression proﬁles of human hematopoietic
lineages, including progenitor populations, highlighted transcrip-
tion modules that distinguish the broad erythroid, myeloid, and
lymphoid classes [4]. We have generated related data based on
meta analysis of human microarray data in the public domain [6].
Microarray-based data enable expression characterization at the
gene level and not at the transcript level. To overcome this
limitation, the FANTOM5 consortium used CAGE to assess
promoter use in numerous primary cells and tissues, including
progenitor and mature myeloid cell populations. CAGE tag
sequencing produces a transcript-speciﬁc expression proxy en-
abling characterization of alternate promoter use [7]. Accordingly,
transcription factors with multiple distinct promoters and distinct
functional isoforms can be associated with their likely targets.
Many widely expressed genes may still have speciﬁc functions in
1. Correspondence: The Roslin Institute and Royal (Dick) School of
Veterinary Studies, The University of Edinburgh, Midlothian EH25 9RG,
Scotland, United Kingdom. E-mail: anagha.joshi@roslin.ed.ac.uk (A.J.);
david.hume@roslin.ed.ac.uk (D.A.H.)
This is an Open Access article distributed under the terms of the Creative
Commons Attribution 4.0 International (CC BY 4.0) (http://creativecommons.
org/licenses/by/4.0/) which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Abbreviations: AML = acute myeloid leukemia, CAGE = cap analysis of gene
expression, CEBPE = CCAAT/enhancer-binding protein, CMP = common
myeloid progenitor, DC = dendritic cell, DHS = DNase I hypersensitivity, EMR1 =
epidermal growth factor-like module-containing mucin-like hormone
receptor-like 1, FANTOM = Functional Annotation of the Mammalian Genome,
FLT3 = fms-like tyrosine kinase-3, FOSB = FBJ murine osteosarcoma viral
(continued on next page)
The online version of this paper, found at www.jleukbio.org, includes
supplemental information.
0741-5400/15/0097-985 © The Author(s) Volume 97, May 2015 Journal of Leukocyte Biology 985
myeloid lineage divergence or cell-speciﬁc function. For example,
differences in expression of metabolic enzymes distinguish subsets
of human monocytes [8]. CAGE sequencing also detects products
of the bidirectional promoter activity of active enhancers [9]. In
this paper, a subset of 91 samples was selected from the FANTOM5
dataset (975 samples) [10], and we have dissected the myeloid cell
populations separately to identify coregulated sets of promoters,
novel enhancers, miRNAs, and noncoding RNAs speciﬁc to
myeloid lineages. We highlight the use of these data to dissect
transcript dynamics during progressive maturation of granulocyte
precursors. The data reveal a much greater level of transcriptional
complexity underlying myeloid lineage divergence than the classic
binary view [11]. This work is part of the FANTOM5 project. Data
download, genomic tools, details of the CAGE library generation
and clustering, and copublished manuscripts are available at
http://fantom.gsc.riken.jp/5/.
MATERIALS AND METHODS
Ninety-one myeloid cell types were selected from the entire FANTOM5 dataset
submitted to the DNA Data Bank of Japan database. They contain 18 distinct
cell types in the myeloid lineage with at least 2 biologic replicates for each cell
type and 22 AML samples. A description of sample preparation, quality
control, and data processing is provided in Supplemental Methods.
Supplemental Table 1 provides the details of each sample, as well as
sequencing details, including number of TSSs identiﬁed in each sample. In
brief, CAGE tags for each library were aligned to the genome (hg19),
neighboring tags were grouped into clusters, and further individual TSSs were
identiﬁed by use of decomposition-based peak identiﬁcations [10]. The TSSs
were annotated based on known transcript 59 ends within 500 bases and
summarized into regions. The TSSs with at least 5 tags/million were selected
for further analysis (details in Supplemental materials). Coexpression
visualization and cluster analysis were performed by use of BioLayout Express3D
[12]. Initially, a sample-to-sample Pearson correlation matrix was calcu-
lated, graphs were visualized at a Pearson correlation cut-off value of 0.58
(see Fig. 2), and nodes were colored according to cell-type grouping to
describe the similarity relations between samples. To identify loose
relationships between samples, a heatmap of sample-to-sample Pearson’s
correlation coefﬁcients was also generated (Supplemental Fig. 1).
Following this, a TSS level analysis was performed. A Pearson correla-
tion matrix was calculated, comparing the expression proﬁles of the
106,709 TSSs, and a correlation cutoff, r = 0.9, was used to construct a
graph. The resultant graph (nodes = 34,868) was then clustered by use
of Markov cluster algorithm [13] with an inﬂation value of 2.2. Clusters
with at least 20 tags and with 5 or more genes were selected for an in-
depth analysis. To gain insights into the transcriptional mechanisms
behind the control of these clusters, we performed cis-regulatory
motif enrichment analysis by use of JASPAR [14, 15] motifs and HOMER [16].
We also calculated enrichment of each cluster with respect to the genome-wide
binding patterns of transcription factors from ENCODE. Bidirectional
expression was used as a proxy for predicting enhancer elements (details in-
Supplemental Methods). The functional enrichment was computed by use of
a hypergeometric test with false discovery rate correction.
To facilitate analysis of the myeloid systems described in this manuscript, we
have made the dataset available at www.myeloidome.roslin.ed.ac.uk. This web
portal consists of 7 analysis tabs, namely, samples, clusters, genome browser,
enhancers, miRNAs, lincRNAs, and granulopoiesis (explained in detail in the
sections to follow). Each analysis tab highlights 1 aspect of use of these data.
For example, the "clusters" tab lists the TSSs and corresponding genes in each
cluster along with cis-regulatory control, whereas the "enhancers" tab provides
cell type-speciﬁc enhancer locations and associated gene predictions. The
"genome browser" tab provides a visualization of the myeloid sample data in
the ZENBU genome browser [17], enabling users to view the expression of
a peak across the 91 myeloid samples. The ZENBU genome browser system
was developed for the FANTOM5 project to enable the interactive exploration
of the FANTOM5 data sets. ZENBU can perform data-processing manipu-
lations to allow the CAGE data to be visualized in many different ways.
RESULTS
Transcriptional proﬁling during normal and
malignant myelopoiesis
To analyze the events in myeloid differentiation, we identiﬁed
a total of 91 progenitor and mature myeloid primary cell
populations and AML cell-line samples from the FANTOM5
dataset. Eighteen distinct cell types in myeloid lineage with at
least 2 biologic replicates for each cell type and 22 AML samples
were then analyzed by use of CAGE to assess promoter use
during myelopoiesis. On average, 4 million CAGE tags mapped
to hg19 assembly in each sample (Supplemental Table 1), and
;7000 TSSs were identiﬁed for each sample.
The sample identity was consistent with expression of known
lineage-speciﬁc growth regulatory receptors elaborated further
with examples. CSF1R encodes the receptor for the macrophage
growth and differentiation factor, M-CSF (CSF1). CSF1R gene
transcription in myeloid cells initiated from a broad, purine-rich
proximal promoter region with low but detectable expression in
puriﬁed HPCs, and in CMPs. CSF1R transcription was induced in
the GMPs, and increased in the transition from classic (CD14+,
CD162) to nonclassic (CD142, CD16+) monocytes. CSF1R was
highly expressed in immature LCs isolated from skin {validated by
their strong expression of CD207 (langerin) and CD1a [18]} and
the monocyte-derived DCs. In contrast, mature LCs isolated from
afferent lymph (CD2072 and CD1a2) and PDCs lacked detectable
CSF1R and instead, expressed FLT3. The absence of CSF1R from
the PDC in humans contrasts with its functional role in PDC in
mice [19]. The FANTOM5 data conﬁrm the existence of an
alternative CSF1R TSS within the 39 UTR of the upstream platelet-
derived growth factor type b-type locus, used speciﬁcally in
trophoblast and placental libraries [20] (data not shown). Across
the dataset, CSF1R expression varies inversely with expression of
FLT3, consistent with proposed roles of the 2 factors in lineage
divergence between monocyte-macrophages and classic DCs [21].
In addition to the mature LCs and the PDCs, FLT3 mRNA was
expressed by HPCs and committed GMPs and in several AML
lines, consistent with its involvement in myeloid leukemia [22]
(Supplemental Fig. 1). The G-CSFR (CSF3R) was highly expressed
(continued from previous page)
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986 Journal of Leukocyte Biology Volume 97, May 2015 www.jleukbio.org
by circulating neutrophils and eosinophils. Neutrophil PMN
samples were puriﬁed from bone marrow and expressed much
lower levels of CSF3RmRNA, implying a large increase in receptor
expression as mature cells enter the circulation. Interestingly,
CSF3R was also expressed by the classic CD14+, CD162 monocytes
but almost ablated in the CD16+ nonclassic subset (Supplemental
Fig. 2). Finally, CD117 (KIT), a surface marker of HPCs, was
expressed in HPCs, CMPs, and GMPs. It was massively expressed in
mast cells, and contrary to reports in the mouse [23], there was
minimal expression in DCs or LCs (Supplemental Fig. 3). As
expected, given the known role of IL-5 in allergy [24], the mast
cells also speciﬁcally expressed high levels of the IL-5R. The EMR1
gene product, recognized by mAb F4/80, is widely used as
a macrophage differentiation marker in mice [25]. Recent reports
have claimed that its expression is restricted to eosinophils in
humans [26]. However, in the FANTOM5 dataset, EMR1
transcription was detected in monocytes but not in eosinophils. It
was elevated in the CD16+ monocyte subset, but by contrast to the
mouse, where it is CSF1 inducible [25], it was ablated in all of the
culture-derived macrophage/DC populations.
In summary, expression proﬁling of known key surface markers
and regulators provides conﬁdence on the identity of the cells
(Fig. 1A) and the biologic relevance of downstream analysis.
Alternate promoter use is a common feature of
transcription regulators
CAGE-based expression proﬁling measures expression at multi-
ple promoters in the same gene locus. We selected TSSs with
more than 5 tags/million in at least 1 sample, resulting in a total
of 106,709 TSSs (from a total of 3.5 million TSSs across 975
samples in the FANTOM5 dataset). Of these, 39,913 (40%)
mapped to promoter regions identiﬁed by GENCODE 19, and
14,755 (15%) were associated with intragenic regions. The TSSs
in the promoter or the gene body were ascribed to that gene
name. The distribution of alternate TSSs to number of genes
shows an approximate power-law relationship with an average of
5 TSSs per gene. The 1500 genes with 10 or more TSSs are
enriched for "transcription regulation" (P value: 4.0e-19),
regulation of apoptosis, and cell death (P value: 4.2e-20). They
include transcription factors, such as FOSB, FOXP1, and KLF6,
and cytokines, such as IL-8 and IL-1B.
In individual samples, on average, 8000 TSSs map to ;6000
unique genes, with an average of 1.2 TSSs per gene. This fraction
is signiﬁcantly lower than the 5 TSSs per gene observed across
multiple cell types (P , 2.2e-16, Fisher test), indicating that
alternate TSSs are used to control cell type-speciﬁc functions.
Eosinophils and neutrophils have the highest number of
expressed TSSs (;11,000) with a ratio of 1.8 TSSs/gene.
Many of the known transcription regulators of myeloid lineages,
including LMO2, RARA, CEBPE, FOXP1, MITF, mothers against
decapentaplegic homolog 2, KLF6, and ETS translocation-variant
gene 6,, have several alternate TSSs, some of which alter the N
terminus of the protein. For example, LMO2 protein is a T cell
oncogene, reportedly expressed in blood and endothelial
progenitors in mice [27]. The human LMO2 gene was reported to
generate 3 alternate transcripts: LMO2-a, -b, and -c (Fig. 1B).
LMO2-a and -b encode for the same 158 aa protein but differ in
the 59 UTR length [28]. The 2 distal TSSs (LMO-a/-b) were
detected in HPCs and the AML samples but differed in relative
expression (Supplemental Fig. 4). They were undetectable in
committed progenitors, CMP or GMP. The same promoters were
used in several CML lines, including K562, included in the primary
FANTOM5 dataset. The proximal LMO2 promoter (LMO-2c), on
the other hand, highlights a function in monocyte differentiation
and lineage divergence. LMO-2c transcript was barely detectable
in progenitor populations (CMP, GMP) and highly expressed in
monocytes but not at all in granulocytes or LCs.
RARA is implicated in myeloid differentiation through its
involvement in the well-characterized t(15;17) translocation,
which produces a promyelocytic leukemia-RARA fusion protein
in AML [29]. At least 5 distinct transcripts with differing 59 ends
have been identiﬁed so far, and all are supported by the CAGE
data. The major TSS is induced in all mature myeloid cells
compared with the low levels in progenitors. Three more
proximal TSSs, as well as antisense transcription associated with
intronic enhancers, are restricted to mature myeloid cells and
Figure 1. Expression of key surface markers and transcription factors
across myeloid lineage. (A) Expression [log2 transcripts per million
(TPM)] of key surface markers and transcription factors across 91
myeloid samples. (B) Normalized CAGE tags in the LMO2 gene locus in
the ZENBU genome browser, highlighting differential expression of the
3 alternate transcripts in myeloid lineage. (C) Normalized CAGE tags in the
MITF gene locus in the ZENBU genome browser with 4 alternate TSSs.
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induced in these cells compared with progenitors (CMP and
GMP). The transcription factor CEBPE has 2 reported pro-
moters, forming multiple isoforms, including an inhibitory one,
regulated by alternate TSS and splicing [30]. The data herein
identiﬁed at least 5 TSSs. However, they were detected only in the
HL60 cell line and were not detected in any primary cell
population. Interestingly, a previous report on the association of
CEBPE mutations in humans with speciﬁc granule deﬁciency in
neutrophils seems to involve ectopic overexpression and does not
imply a physiologic function [31].
Monocytes and macrophages in the mouse express all
4 members of the MITF family (MITF, TFEC, TFEB, and TFE3)
[32], and these gene products have been implicated in
regulating phagocyte-speciﬁc promoters associated with lyso-
somal hydrolases. All 4 members of the MITF family were
differentially regulated in human myeloid cells from alternative
promoters. MITF itself was expressed in differentiated macro-
phages and mast cells from the most distal of the 4 promoters
(Fig. 1C). As reported in the mouse [21], TFEC is a monocyte-
macrophage differentiation marker and absent from progenitors
or granulocytes. These data conﬁrm the existence of a 100 kb
upstream TSS within the TFEC locus, also restricted to monocyte-
macrophages. Finally, TFEB has several promoters, all of which
were detected in myeloid cells. The expression was absent from
stem cells and progenitors and induced in monocytes and
granulocytes but not in mast cells. The MITF proteins can form
heterodimers and homodimers with other MITF family members
[33] and can interact with other lineage-speciﬁc factors, such as
PU.1, so their complex expression pattern provides considerable
scope for combinatorial function.
Sample level analysis identiﬁes signature gene sets in
myeloid cells
To establish relatedness among the 91 samples, we created
a sample-to-sample correlation matrix. The visual representation
of this matrix at Pearson correlation coefﬁcient cutoff of 0.58 by
use of BioLayout Express3D [12] shows that different samples of the
same or related cell type, such as neutrophils and eosinophils,
cluster together (Fig. 2A). Monocyte-derived macrophages (grown
in CSF-1), DCs (grown in GM-CSF), and endothelial progenitors
(grown in vascular endothelial growth factor) form 1 tight cluster.
The monocyte samples cluster together regardless of the ex-
pression of CD16 or partial activation. The progenitor cells cluster
together and lie closest to the AMLs, with which they share
expression of cell cycle-related genes, such as proliferating cell
nuclear antigen (data not shown). The dataset includes 3 mast cell
populations, primary cells, and cells expanded in vitro and
stimulated via the FceR1. Although they exhibit quite distinct gene-
expression proﬁles [34], the cluster analysis reveals their re-
latedness to each other and distinguishes them from other
myeloid populations.
Three sequence motifs (PU.1, GABPA, and TATA-binding
protein) were enriched in all samples. PU.1 (SPI1) is an essential
regulator controlling diverse aspects of early hematopoiesis and
myeloid cell differentiation. The PU.1-expressing CMPs were
found to have myeloid potential, whereas PU.1-deﬁcient CMPs
had erythroid potential, suggesting that PU.1 expression deter-
mines the developmental fate of a CMP [35]. Likewise, GABPA is
also a key transcription factor required for myeloid differenti-
ation [36]. Apart from these globally enriched transcription
factor motifs, 6 motif families were restricted to 1 or a few cell
types (Fig. 2B). For example, the E2F motif is enriched in
progenitor populations and AML, whereas the GATA motif is
enriched only in mast cells. GATA-1 and -2 have long been
known for their importance in mast cell development (masto-
poiesis) and mast cell function (such as cytokine responses),
where a multitude of mast cell marker genes (FCER1A, MS4A2,
KIT, and IL-1RL1/ST2) depends on GATA-1 and/or -2 for their
transcription. The "samples" analysis tab in the web browser
provides the genes and TSSs in each of 19 cell types together
with genes speciﬁcally up- and down-regulated in that cell type,
along with the predicted transcription regulators in each
sample.
Clustering of coexpressed TSSs
To identify sets of promoters that share transcriptional regulation
[37], we used the clustering tool BioLayout Express3D [12] to
identify 162 clusters of coexpressed TSSs (Fig. 3A). Over 100
clusters contained TSSs highly expressed only in 1 or a few cell
types (Supplemental Table 2). For example, cluster 1 was CD14+
monocyte speciﬁc, whereas cluster 2 was neutrophil and eosino-
phil speciﬁc. Cluster 68 distinguished LCs from other myeloid
cell types, whereas clusters 13 and 20 further distinguished
between the 2 LC populations (described in detail below). Several
clusters contain genes highly expressed in a single AML sample,
demonstrating that each AML sample has its unique signature
genes. The clusters tab of the web browser provides the TSS
positions, corresponding genes, predicted transcription regulators,
as well as a graphical representation of the average expression
dynamics for all clusters. We noted the presence of well-known
transcription factors in multiple clusters, demonstrating the
prevalence of use of alternate promoters to achieve cell type-
speciﬁc gene regulation (Fig. 3B). For example, different pro-
moter use by GFI1 places it into 2 clusters: cluster 11 and 86
(Fig. 3C). Cluster 11 consists of genes highly expressed only in
PDCs, whereas cluster 86 consists of genes highly expressed in
neutrophils. With the use of the ENCODE chromatin immuno-
precipitation sequencing data and cis-regulatory motif enrichment,
we predict TCF family members to regulate cluster 11. TCF family
members control developmental processes by forming homo- or
heterodimers with other E proteins, such as the development of
T cells, B cells, and PDCs at a transcriptional level [38]. TCF4
belongs to cluster 11.
As noted above, the LC populations are distinguished from
each other and from monocyte-derived DCs by their relative
expression of CSF1R and FLT3. The LCs contribute to 2 large
clusters—13 and 20—that distinguish the LC from monocyte-
derived DC and other cell populations (Fig. 3A). Both clusters
contain CD207 (langerin), expressed from distinct promoters.
Cluster 13 contains a set of promoters highly enriched in the
mature LC, lower in the “immature” LC, and largely absent from
monocyte-derived DCs. The cluster includes CCR7, the central
regulator of DC migration [39, 40]; the transcription factor
RELB, also associated with DC function in humans [41]; as well as
many class II MHC genes. Cluster 20 is enriched in the immature
LC relative to migratory DC and interestingly, contains a distinct
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CSF1R promoter, as well as CD1a, many other class II MHC genes,
and the transcription factor class II, MHC, transactivator.
Enhancer analysis in the myeloid lineage predicts cell
type-speciﬁc enhancers downstream of 2 key regulators:
IRF8 and KIT
CAGE tag proﬁling detects candidate enhancers based on
bidirectional transcription [9]. From the large FANTOM5
dataset, 20,301 enhancers were active in myeloid lineages (the
complete list is available from the web resource). For the small
number of genes studied in detail previously, the results conﬁrm
prior knowledge. For example, the data conﬁrm the presence of
a major myeloid-speciﬁc enhancer ;16–17 kb upstream of the
major TSS of PU.1 (SPI1), the location of a SNP that is more
frequent in AML patients [42]. Supplemental Table 3 shows
a further 10 of our enhancer regions that overlapped with a set of
2000 high-conﬁdence enhancers identiﬁed by ENCODE [43].
Not surprisingly, as the enhancer predictions from ENCODE
come from diverse sets of cell types, these 10 regions were active
across multiple cell types and were associated with housekeeping
genes and cell-cycle machinery, such as cell division protein
kinase 6. Among the set of enhancers detected in myeloid cells,
196 were clearly restricted to a speciﬁc cell type. One-half of
these was restricted to eosinophils and neutrophils. The genomic
location, associated gene, as well as the expression proﬁle across
myeloid lineages of these putative enhancers are available from
the enhancers tab of the web resource.
One example of these lineage-speciﬁc enhancers is asso-
ciated with IRF8. The IRF8 mRNA was expressed in GMPs and
maintained in monocytes. IRF8 mutations in humans are
associated with monocyte deﬁciency [44], including a SNP
associated with variation in the monocyte count in humans [45].
It was induced further in PDCs but was switched completely off in
granulocytes (Supplemental Fig. 5). With the reinforcement of
the complex interactions of enhancers and promoters, at least
5 candidate enhancers are evident upstream, downstream, and
within introns of the IRF8 locus. We focused on a candidate
enhancer region (chr16:85969764-85970393; hg19), speciﬁcally
active in GMPs (Fig. 4). This enhancer is located 38 kb
downstream of the IRF8 gene TSS and was associated with IRF8,
Figure 2. Sample clustering and cis-regulatory
sequence motif enrichment. (A) . Clustering and
visualization of 91 myeloid samples with the Pearson
correlation cutoff of 0.58 by use of BioLayout
Express3D, highlighting the replicates as well as
related sample clusters together. PCDC, plasmocy-
toid dentritic cells. (B) Cis-regulatory sequence
motif enrichments along with sequence logos
enriched only in speciﬁc cell type(s) calculated by
use of HOMER software. TF, Transcription factor;
BZIP, basic region-leucine zipper motif; HLH, helix-
loop-helix.
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based on coexpression [9] (Fig. 4 and Supplemental Fig. 6A). In
the FANTOM4 study of THP1 monocytic differentiation to
macrophages in response to PMA, this enhancer was identiﬁed as
a site of H3K9 acetylation based on whole genome tiling arrays
[38]. The peak of H3K9 acetylation was reduced as IRF8
expression was extinguished in response to PMA. This region was
the only one marked by H3K27Ac (a chromatin mark associated
with active enhancers) in the otherwise repressed locus (as
indicated by H3K27me3) in HPCs. It was strongly associated with
H3K27Ac, DHS (indicating transcription factor binding), in
IRF8-expressing monocytes and B cells and bound by PU.1 in
monocytes (Fig. 4), a factor recently implicated in the remodel-
ing of the IRF8 locus [46] (Supplemental Fig. 6B). The candidate
enhancer is also highly conserved between human and mouse
(ecrbrowser.dcode.org) and also marked as a PU.1-bound
enhancer in mouse macrophages (Supplemental Fig. 6C). The
data outlined above indicate that this bidirectionally transcribed
region acts as an enhancer that is most likely associated with
transcriptional activation of the IRF8 gene during hematopoietic
differentiation. Another example is of an enhancer region chr4:
55527478-55527674 (hg19), speciﬁc to mast cells, located 3.5 kb
downstream of the main promoter of KIT (in the ﬁrst intron)
that shows an expression correlation with the KITmain promoter
(Supplemental Fig. 7). This region is highly conserved across 100
vertebrates, including 2 highly conserved transcription factor-
binding sites (Supplemental Fig. 7), supporting its role as
a regulatory region. Moreover, this region is bound by FOS,
STAT3, and FOXP2 in the MCF10A-Er-Src cell line and contains
a strongly enriched DNase-hypersensitive site from ENCODE
data. This developmental gene locus has been characterized in
great detail for cell type-speciﬁc chromatin looping [47].
Transcription dynamics of miRNAs and noncoding
RNAs in myeloid lineages
Many short, noncoding RNAs, in particular, miRNAs, act at the
post-transcriptional level to control gene expression. Two hundred
eleven miRNAs are expressed in myeloid lineages, including
known regulators, during myelopoiesis. For example, miR-223 is
preferentially expressed in myeloid cells and is involved in
granulopoietic regulation [48]. lincRNAs also function in tran-
scriptional regulation through several mechanisms. To identify
robust, myeloid-speciﬁc lincRNAs, we ﬁrst identiﬁed a set of
CAGE-deﬁned TSSs that do not lie within a gene body or
promoter region of protein-coding genes, and 6286 of these were
found to overlap with lincRNA locations from ENSEMBL. The list
of miRNAs and lincRNAs expressed in myeloid lineages, along
Figure 3. Gene clustering and alternate transcrip-
tion regulation. (A) The clustering and visualiza-
tion of all TSSs by use of BioLayout Express3D, with
each of the TSSs belonging to each of 162 clusters
indicated in a different color. (B) Expression
proﬁles of 4 clusters (clusters 11, 13, 20, and 86)
across 91 myeloid samples, indicating that many
clusters are expressed in a speciﬁc cell type,
providing a list of signature genes for that cell
type, including distinction between immature and
mature LCs (Clusters 13 and 20). (C) Four
transcription factors with cell type-speciﬁc alter-
nate transcripts across 91 cell types grouped into
11 subgroups labeled on the x-axis. The 2
(colored) proﬁles in each panel indicate 2
alternate transcripts expressed in distinct cell
types. For example, Gﬁ1 places it into clusters 11
(expression proﬁle in brown color) and 86
(expression proﬁle in green color). Cluster 11
consists of genes highly expressed only in PDCs,
whereas cluster 86 consists of genes highly
expressed in neutrophils.
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with their expression proﬁle, is available from the "miRNAs" and
"lincRNAs" tabs within the web resource, respectively.
To validate these datasets against current literature, we exam-
ined the HOX gene clusters, known for the prevalence of its
intergenic, noncoding transcription. miRNAs and lincRNAs have
been identiﬁed as regulators of HOX genes [49]. miRNA-196 was
expressed speciﬁcally only in AML and progenitor cell populations
(Supplemental Fig. 8), in keeping with evidence that miR-196a and
miR-196b contribute to hematopoietic differentiation, prolifera-
tion, and AML [50]. On the 59 and 39 edges of the HOXA cluster,
there are 2 lincRNA loci: the 39 element called HOTAIRM1 [51]
and the 59 element called HOTTIP [52]. HOTAIRM1 is expressed
speciﬁcally in myeloid lineage of the hematopoietic tree [51], and
was detectably transcribed in all 91 samples (Supplemental Fig. 9).
HOTTIP is a 3764 nucleotide, spliced, polyadenylated RNA,
transcribed just upstream of HOXA13, and was expressed
speciﬁcally in AML samples (Supplemental Fig. 10).
Transcriptional dynamics during granulopoiesis
The dataset provides a development of the granulocyte series,
from HPCs through CMPs to promyelocytes and segmented
neutrophils in the marrow and thence, to mature neutrophils
in the circulation (Fig. 5A). We clustered 11,091 genes,
dynamically expressed in the granulopoiesis series, to identify
38 sets of coexpressed gene sets. The expression clusters
detected with CAGE are entirely consistent with the literature
on progressive maturation of granulocytes [53] (Fig. 5B). We
highlight this case by use of exemplar clusters that exhibit
a clear, stage-speciﬁc expression proﬁle (Fig. 5C). The ﬁrst
cluster (cluster 3) is HPC speciﬁc and proximal to cluster 4,
which contains RUNX1 and T cell acute lymphocytic leukemia
1, the 2 transcription factors indispensable for generating
HPCs [35]. The down-regulation of these stem cell-speciﬁc
genes during granulopoiesis is consistent with the ability of
RUNX1 to suppress myelopoiesis [35]. The second cluster
(cluster 5), enriched in CD34+ progenitor cells, showed
a functional enrichment for positive regulation of cell pro-
liferation (P value: 1.4e-3) and contains transcription factors,
such as JUN and NMYC. The third cluster (cluster 18) was
enriched for mitochondrial matrix and lumen (P value: 7.7e-7)
and contains the primary granule genes, such as myeloperox-
idase, that are known to be highly expressed in GM
Figure 4. The +38 kb enhancer downstream of the IRF8 gene locus. Normalized CAGE tag counts in the IRF8 gene locus across selected myeloid samples with
a zoom-in view of the putative +38 kb enhancer element associated with the IRF8 gene. The view also indicates peaks in this enhancer region for DHS, as well as
H3K27ac (enhancer mark) in HPC and mature cell types. Moreover, there is PU.1 binding at the +38 kb enhancer region (the last track). MOc, monocytes.
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progenitors, whereas the fourth cluster (cluster 38), enriched for
response to microbicidal activity (P value: 1.7e-3), contains
secondary granule proteins, such as lactoferrin, expressed in
promyelocytes and marrow neutrophils and down-regulated in
circulating neutrophils. The tertiary granule protein matrix
metalloproteinase 9 and the components of the phagocyte
oxidase, such as cytochrome B-245, are induced only at the
marrow neutrophil stage and belong to the ﬁfth cluster (cluster
11). Finally, chemotactic factor receptors, such as the formyl
peptide receptor 1 and the complement receptor 1, are induced
on blood neutrophils (as well as eosinophils, basophils, and CD14+
monocytes) and belong to the sixth cluster (cluster 1), enriched
for inﬂammation response (P value: 1.4e-8) and myeloid
leukocyte activation (P value: 1.2e-6). On the principle of guilt by
association, other genes in these clusters, including those with
little informative annotation, are likely to have functions in
granulocyte maturation (for example, potential partners of the
key transcription factors). Therefore, we have provided the lists
of genes, including transcription factors and miRNAs, along with
the graphical representation of the expression proﬁle, for each
cluster in the "granulopoiesis" tab of the web resource.
DISCUSSION
Myeloid cells are essential players in innate immunity, derived from
a common, committed progenitor. The FANTOM5 dataset includes
hematopoietic progenitors and many distinct mature, primary
human cell populations of myeloid origin, as well as diverse AML
lines. We further validated sample identity by expression proﬁles of
key surface markers, such as CSF1R, and CSF1R expression was
largely excluded from various granulocyte lineages and mast cells.
This ﬁnding contrasts with mouse granulocytes, where CSF1R
mRNA (but not CSF1R protein) is highly expressed [54].
Nevertheless, many genes expressed outside of the myeloid lineages
distinguish myeloid cell types and may use distinct promoters and
enhancers. We have carried out a more-detailed analysis of this
subset of FANTOM5 data, permitting the identiﬁcation of novel
transcripts, transcription factors, miRNAs, and noncoding RNAs
speciﬁc to individual myeloid cell types that can be used as markers
of differentiation. With the use of the bidirectional expression as
a proxy for enhancers, we predicted over 2000 novel enhancers,
including a +38 kb enhancer in the IRF8 and an intronic enhancer
in the KIT gene locus. Finally, we highlighted relevance of these data
Figure 5. Temporal expression dynamics during
granulopoiesis. (A) The clustering of samples and
visualization of granulopoiesis by use of BioLayout
Express3D , highlighting the replicates that cluster
together (HPC, red; CMP, blue; promyelocytes,
green; PMN neutrophils, yellow; mature neutro-
phils, purple), and the samples follow the matura-
tion/developmental order (from left to right)
during granulopoiesis. (B) The clustering of genes
and visualization of granulopoiesis by use of
BioLayout Express3D, with a few exemplar clusters
numbered. (C) The expression proﬁle for 6
clusters: cluster 3, 5, 18, 38, 11, and 1, serially
expressed during the granulopoiesis series.
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to dissect transcription dynamics during progressive maturation of
granulocyte precursors. We have made all analysis available to the
research community through a web resource.
SNPs associated with human disease susceptibility in genome-wide
association studies are associated with promoters and enhancers
[9, 10]. Perhaps the greatest use of the FANTOM5myeloid dataset is
for a detailed (re)analysis of individual loci associated with human
inﬂammatory diseases for hypothesis generation. For example,
variation at the NOD2 (caspase recruitment domain-containing
protein 15) has been associated with susceptibility to Crohn’s disease
[55]. The FANTOM5 data reveals that NOD2 is monocyte speciﬁc,
and expression is ablated in monocyte-derived macrophages.
Interestingly, NOD2 is located head to head with SNX20. A single
report in the literature implicated SNX20 in P selectin-mediated
myeloid cell adhesion [56]. There are 4 myeloid-speciﬁc enhancers
between the 2 genes, and they are perfectly coexpressed. Hence,
SNX20 may contribute to Crohn’s disease susceptibility associated
with variation at this locus.
Taken together, the high-quality dataset provides a powerful resource
to study transcriptional regulation during myelopoiesis and to infer the
likely functions of unannotated genes in human innate immunity.
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